Eric Schadt | Mount Sinai

Biography

Research Topics

Bioinformatics, Computational Neuroscience, Epigenetics, Genetics, Human Genetics and Genetic Disorders

Publications

532

Publications

Selected Publications

Proteomic-based stemness score measures oncogenic dedifferentiation and enables the identification of druggable targets. Iga Kołodziejczak-Guglas, Renan L.S. Simões, Emerson de Souza Santos, Elizabeth G. Demicco, Rossana N. Lazcano Segura, Weiping Ma, Pei Wang, Yifat Geffen, Erik Storrs, Francesca Petralia, Antonio Colaprico, Felipe da Veiga Leprevost, Pietro Pugliese, Michele Ceccarelli, Houtan Noushmehr, Alexey I. Nesvizhskii, Bożena Kamińska, Waldemar Priebe, Jan Lubiński, Bing Zhang, Alexander J. Lazar, Paweł Kurzawa, Mehdi Mesri, Ana I. Robles, Alicia Francis, Amanda G. Paulovich, Anna P. Calinawan, Antonio Iavarone, Arul M. Chinnaiyan, Bo Wen, Boris Reva, Brian J. Druker, Caleb M. Lindgren, Chandan Kumar-Sinha, Chelsea J. Newton, Chen Huang, Chet Birger, Corbin Day, D. R. Mani, Daniel Cui Zhou, Daniel W. Chan, David Fenyö, David I. Heiman, Dmitry Rykunov, Emily Huntsman, Eric E. Schadt, Eric J. Jaehnig, Shrabanti Chowdhury, Xiaoyu Song, Zeynep H. Gümüş. Cell Genomics

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj. Cancer Discovery

Precision proteogenomics reveals pan-cancer impact of germline variants. Fernanda Martins Rodrigues, Nadezhda V. Terekhanova, Kathleen J. Imbach, Karl R. Clauser, Myvizhi Esai Selvan, Isabel Mendizabal, Yifat Geffen, Yo Akiyama, Myranda Maynard, Tomer M. Yaron, Yize Li, Song Cao, Erik P. Storrs, Olivia S. Gonda, Adrian Gaite-Reguero, Akshay Govindan, Emily A. Kawaler, Matthew A. Wyczalkowski, Robert J. Klein, Berk Turhan, Karsten Krug, D. R. Mani, Felipe da Veiga Leprevost, Alexey I. Nesvizhskii, Steven A. Carr, David Fenyö, Michael A. Gillette, Antonio Colaprico, Antonio Iavarone, Ana I. Robles, Kuan lin Huang, Chandan Kumar-Sinha, François Aguet, Alexander J. Lazar, Lewis C. Cantley, Urko M. Marigorta, Zeynep H. Gümüş, Matthew H. Bailey, Gad Getz, Eduard Porta-Pardo, Li Ding, Eunkyung An, Meenakshi Anurag, Jasmin Bavarva, Shrabanti Chowdhury, Francesca Petralia, Boris Reva, Eric E. Schadt, Xiaoyu Song, Pei Wang. Cell

View All Publications

Video

Strata RX 2012 - Eric Schadt Keynote - Wednesday 10/17/1

Eric Schadt-The effects of meditation at molecular cellular levels.

Math, Medicine, Motorcycles: Eric Schadt Takes the Fast Lane

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Schadt during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

GeneDx
Pathos

Founder/Co-Founder/Partner

GeneDx

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Schadt during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

GeneDx
Pathos

Founder/Co-Founder/Partner

GeneDx

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.